Mel Snyder: Beyond Sickle Cell Disease to the Future of Pediatric Genetics
Mel Snyder, Healthcare Commercialization and Strategy Advisor at ProClinica Inc., shared a post on LinkedIn:
“Now, more than 5000 American children with sickle cell disease can access a genetic cure for a disease that causes pain, organ damage, loss of school days, ans limited participation in sports and other childhood activities.
Possibly more important: The FDA’s action on Casgevy/Sickle-Cell Disease suggests a more liberal view of extending to pediatric patients other genetic cures until now reserved for adults.
Since the vast majority of genetic diseases first appear in infants, this FDA action may encourage more investment in public and private biopharmas working on agents for other genetic diseases first seen in childhood.”

Stay updated with Hemostasis Today.
-
Nov 16, 2026, 11:53Eduardo Ortiz Bello: The Endothelium in Hemostasis and Microcirculation
-
Nov 16, 2026, 11:51Phil Spinella: Advancing Transfusion Medicine Through Collaboration
-
Nov 16, 2026, 11:46Madiha Chowdhury: Behind the Scenes of Blood Transfusion Services
-
Nov 16, 2026, 11:43Nasir Al Allawi: Honouring Excellence in Haematopathology
-
Nov 16, 2026, 11:39Osman El-Maarri: Delete Two Genes from a Cell Line and It Secretes Twice as much Factor VIII
-
Nov 16, 2026, 11:37Chaza Alaji: Unexplained Bruising-Beyond Platelet Counts and Coagulation Tests
-
Nov 16, 2026, 11:33Obed Asumadu: How Can Advanced Laboratory Diagnostics Improve the Detection and Management of Haemophilia?
-
Nov 16, 2026, 11:29Amman Yousaf: Pulmonary Embolism Mortality in Patients With Coagulation Disorders at AHA 2026
-
Nov 16, 2026, 10:48Tareq Abadl: Why the Kell Blood Group System Matters